Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer

Cancer medicine

Volumn 3, Issue 3, 2014, Pages 572-579

  Cardin, Dana B ^a   Goff, Laura ^a   Li, Chung I ^a   Shyr, Yu ^a   Winkler, Charles ^a   DeVore, Russell ^a   Schlabach, Larry ^a   Holloway, Melanie ^a   McClanahan, Pam ^a   Meyer, Krista ^a   Grigorieva, Julia ^a   Berlin, Jordan ^a   Chan, Emily ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Erlotinib; pancreatic cancer; sorafenib; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NICOTINAMIDE; QUINAZOLINE DERIVATIVE; SORAFENIB;

ADULT; ADVERSE DRUG REACTION; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NIACINAMIDE; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925545429     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.208     Document Type: Article

References (0)